Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
167 hedge funds and large institutions have $2.5B invested in Intercept Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 63 increasing their positions, 52 reducing their positions, and 11 closing their positions.
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
71% more call options, than puts
Call options by funds: $112M | Put options by funds: $65.7M
21% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 52
11% more funds holding
Funds holding: 150 → 167 (+17)
5% more capital invested
Capital invested by funds: $2.38B → $2.5B (+$118M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$19.2M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.2M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
+$9.4M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$8.55M |
| 5 |
BlackRock
New York
|
+$7.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$42.1M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$36.4M |
| 3 |
O
OrbiMed
New York
|
-$20.9M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$10.3M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$7.68M |
ICPT Hedge Fund Activity: Q2 2017 in Review
167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q2 2017, worth a combined $2.5B — up 5% from $2.38B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ICPT positions and 11 closed out — a net gain of 17 holders — while 63 added to existing stakes and 52 trimmed.
The largest buyer was Millennium Management, adding an estimated $19.2M. The largest seller was JP Morgan Chase, cutting an estimated $42.1M.
- 167 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q2 2017, up from 150 in Q1 2017.
- Funds reported $2.5B of Intercept Pharmaceuticals, Inc. stock for Q2 2017, up 5% quarter-over-quarter.
- 28 funds opened new Intercept Pharmaceuticals, Inc. positions in Q2 2017 and 11 closed out, a net change of +17 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q2 2017 was Millennium Management, an estimated $19.2M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q2 2017 was JP Morgan Chase, an estimated $42.1M sold.
Based on aggregated 13F filings for Q2 2017.